FIL Ltd grew its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 262.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,961,416 shares of the medical research company's stock after acquiring an additional 1,420,102 shares during the quarter. FIL Ltd owned 1.29% of Bruker worth $114,978,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Bruker in the fourth quarter valued at approximately $63,378,000. Vaughan Nelson Investment Management L.P. boosted its stake in Bruker by 140.3% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after purchasing an additional 666,617 shares during the period. State Street Corp increased its holdings in Bruker by 9.6% during the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock worth $250,501,000 after purchasing an additional 318,808 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Bruker by 139.3% in the 4th quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company's stock valued at $30,844,000 after purchasing an additional 306,282 shares during the period. Finally, Brown Brothers Harriman & Co. lifted its holdings in shares of Bruker by 37.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 829,763 shares of the medical research company's stock valued at $48,641,000 after purchasing an additional 227,619 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on BRKR shares. Citigroup dropped their target price on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Barclays lowered their price target on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Thursday. Guggenheim reissued a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Stifel Nicolaus lowered their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $66.50.
Check Out Our Latest Analysis on BRKR
Bruker Stock Performance
Shares of BRKR traded up $0.69 during trading hours on Friday, hitting $38.76. The company had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,987. The business has a fifty day moving average of $46.16 and a 200-day moving average of $54.75. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The firm has a market cap of $5.88 billion, a price-to-earnings ratio of 51.00, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a 12 month low of $34.10 and a 12 month high of $90.03.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.
Bruker Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.52%. Bruker's dividend payout ratio is presently 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Recommended Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
